Meihua International Medical Technologies Co., Ltd.

MHUAF Healthcare Medical Instruments & Supplies

Meihua International Medical Technologies Co., Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $61.8 million, down 36.2% from fiscal 2024.

6.50 0.00 0.00%
Market cap
$4.3M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
2.00
Beneish M
−1.79
Dividend safety
n/a

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 98.83%

Capital & Financial Ratios $m

Market Cap 4.25
Revenue —
Net Income 25.47
Free Cash Flow 6.15
Net Debt (6.17)
Current Ratio 8.42 (at or above 1.5: strong)
Debt/Equity 0.05 (at or below 0.5: strong)
P/E ratio —
Fwd P/E —
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth (28.31%) (below 0%: weak)
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (1.00%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2022 2023 2024 2025
Cash 27 17 17 15
Receivables 91 99 115 119
Inventory 1 2 1 2
Other 16 14 10 —
135 132 143 154
2022 2023 2024 2025
Payables 16 16 15 8
ST’ Debt 6 7 8 9
Other 1 — 1 —
24 25 27 18

Compound Annual Growth %

10y 5y 3y
Sales — (7.05%) (15.75%)
Cash Flow — (36.04%) 0.00%
Earnings — (18.66%) 2.80%
Book Value — 17.39% 10.86%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 62
’24 — — — — 97
’23 — — — — 97
’22 — — — — 103
’21 — — — — 104
’20 — — — — 89
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 1
’24 — — — — 15
’23 — — — — 2
’22 — — — — (9)
’21 — — — — 0
’20 — — — — 5
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — (10) — 1 1
’24 — 1 — 15 15
’23 — (6) — 1 (2)
’22 — — — (12) (12)
’21 — — — (1) (1)
’20 — — — (11) (11)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 18.04
’24 — — — — 40.00
’23 — — — — 49.00
’22 — — — — 27.00
’21 — — — — 100.00
’20 — — — — 95.23
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — — 260.00 133.00 25.00 2.05

Analyst estimates 2026–2028

Powerpack
High — — — — — — 1,493.60 4,549.00 154.00 64.00
People
People Employees — — — — 629 622 626 617 619 486
Revenue/emp, $m — — — 0.00 0.14 0.17 0.17 0.16 0.16 0.13
Income, $m
Income, $m Revenue — — — 80 89 104 103 97 97 62
Gross margin, % — — — 40.10 41.72 38.26 36.86 34.19 34.36 31.01
EBT — — — 19 24 26 11 15 14 9
EBT margin, % — — — 24.18 26.65 25.21 10.54 15.50 14.06 15.22
Net income — 0 — 15 19 21 6 12 11 7
Depreciation — — — 1 1 1 1 0 1 1
Per share, $
Per share, $ Revenue — — — 3.30 445.31 520.19 441.46 405.59 354.07 164.34
Earnings — — — 0.64 95.23 100.00 27.00 49.00 40.00 21.26
Cash flow — — — 0.39 26.63 (0.27) (39.14) 9.51 53.48 1.52
Capex — — — 0.00 (80.47) (4.17) (11.43) (18.12) (0.49) (0.04)
Free cash flow — — — 0.39 (53.84) (4.44) (50.57) (8.62) 52.99 1.47
Book value — — — 2.47 423.68 538.84 592.39 613.36 580.84 502.48
Shares, m — — — 24 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E — — — — — — — — — —
P/S — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/B — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF — — — 0.00 0.00 0.00 0.00 0.51 (0.79) (0.88)
Cash, $m
Cash, $m Operating cash flow — — — 9 5 0 (9) 2 15 1
Capex — — — (9) (16) (1) (3) (4) 0 0
Free cash flow — — — 9 (11) (1) (12) (2) 15 1
Balance, $m
Balance, $m Working capital — — — 39 46 68 111 107 116 135
Total debt — — — 3 3 5 7 7 8 9
Net debt — — — (13) (4) (3) (20) (10) (9) (6)
Shareholders’ equity — — — 60 85 108 139 147 159 189
Returns, %
Returns, % ROA — — — 42.16 21.25 17.25 4.16 6.93 6.06 3.45
ROIC — — — 0.00 18.16 15.66 5.68 6.68 5.98 2.83
ROE — — — 21.37 26.38 21.77 5.07 8.14 7.09 3.90
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025

Charts ten years each

Meihua International Medical Technologies Co., Ltd. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RVP Retractable Technologies, Inc. $17.6M — (loss-making) 11.1× −31.07% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 2.65% (71.46%) Compare
BNGO Bionano Genomics, Inc. $16.1M — (loss-making) — (loss-making) +21.36% (above 0%: growing) n/m −33.93% (below 0%: shrinking) 52.80% (88.34%) Compare
NXGL NexGel, Inc. $15.9M — (loss-making) — (loss-making) +27.81% (above 0%: growing) n/m −432.32% (below 0%: shrinking) 30.09% (67.96%) Compare
FEMY Femasys Inc. $14.5M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +11.29% (above 0%: growing) 57.08% (1,526.79%) Compare
CUPR Cuprina Holdings (Cayman) Limited $11.5M — — — — — — — Compare
RGNT Regentis Biomaterials Ltd. $10.9M — — — — −132.79% (below 0%: shrinking) — — Compare
LUCY Innovative Eyewear, Inc. $7.3M — (loss-making) — +74.46% (above 0%: growing) n/m +9.61% (above 0%: growing) 24.00% (168.73%) Compare
MHUAF Meihua International Medical Technologies Co., Ltd. $4.3M — — — — −61.55% (below 0%: shrinking) 35.48% 0.00%
GCTK GlucoTrack, Inc. $840.0K — (loss-making) — (loss-making) +342.48% (above 0%: growing) n/m +3.42% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $13.0M — — +24.59% — +3.42% 27.04% (79.90%)

All 55 Medical Instruments & Supplies stocks →

Meihua International Medical Technologies Co., Ltd. (MHUAF) key facts

  • Concern: Meihua International Medical Technologies Co., Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $61.8 million, down 36.2% from fiscal 2024.
  • Meihua International Medical Technologies Co., Ltd. (MHUAF) is a Medical Instruments & Supplies company in the Healthcare sector.
  • As of October 15, 2026, MHUAF traded at $6.50, a market capitalization of $4.3 million.
  • Return on equity was 3.90% and debt-to-equity 0.05.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 2.00 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Meihua International Medical Technologies Co., Ltd. (MHUAF) Latest News

No news at this impact. Lower the threshold for more.

stockrow.com/MHUAF · Data as of Dec 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com